Summary of patient characteristics
| Pt ID . | Sex . | Age, y . | CTCL subtype . | Current therapy . | Previous therapy . |
|---|---|---|---|---|---|
| 1 | M | 73 | FMF | ECP | None |
| 2 | M | 84 | SS | Brentuximab, vorinostat | PUVA, ECP, vorinostat, MTX, bexarotene, IFNα-2b, romidepsin, gemcitabine/doxorubicin, alemtuzumab |
| 3 | M | 66 | SS | ECP | NB-UVB, topical steroids |
| 4 | M | 85 | SS | ECP | Topical steroids |
| 5 | F | 71 | SS | Gemcitabine | ECP, bexarotene, topical steroids, IFNα-2b, vorinostat, romidepsin, belinostat |
| 6 | M | 73 | SS | Pralatrexate | Romidepsin, ECP, bexarotene, topical steroids |
| 7 | F | 61 | SS | ECP, bexarotene | Topical steroids, phototherapy |
| 8 | M | 77 | SS | Romidepsin, vorinostat | ECP, NB-UVB |
| 9 | M | 70 | SS | Pralatrexate | Romidepsin, vorinostat, mechlorethamine, ECP |
| 10 | M | 71 | MF | ECP, bexarotene | NB-UVB, topical steroids |
| 11 | F | 79 | SS | ECP, bexarotene, vorinostat, INFα-2b | Topical steroids |
| 12 | F | 64 | SS | ECP, bexarotene | Topical steroids |
| 13 | F | 76 | SS | ECP | None |
| 14 | M | 61 | MF | ECP, NB-UVB | None |
| 15 | M | 67 | SS | ECP, bexarotene | None |
| 16 | F | 40 | FMF | ECP, bexarotene | NB-UVB, TSEBT |
| 17 | M | 66 | SS | ECP, bexarotene, NB-UVB, topical steroids | None |
| 18 | F | 64 | MF | ECP, bexarotene, IFNα-2b, IFNγ-1b | None |
| 19 | M | 87 | MF | ECP | MTX, bexarotene, topical steroids |
| 20 | M | 85 | MF | ECP, bexarotene, NB-UVB | Topical steroids |
| 21 | M | 70 | MF (V) | EPOCH | None |
| 22 | M | 77 | MF | ECP, bexarotene | NB-UVB, topical steroids |
| 23 | M | 52 | MF | Gemcitabine | NB-UVB, bexarotene, vorinostat, ECP, IFNα-2b, romidepsin, |
| 24 | F | 62 | MF | ECP, bexarotene, NB-UVB, mechlorethamine | Topical steroids |
| 25 | M | 62 | MF | ECP, bexarotene | Topical steroids |
| Pt ID . | Sex . | Age, y . | CTCL subtype . | Current therapy . | Previous therapy . |
|---|---|---|---|---|---|
| 1 | M | 73 | FMF | ECP | None |
| 2 | M | 84 | SS | Brentuximab, vorinostat | PUVA, ECP, vorinostat, MTX, bexarotene, IFNα-2b, romidepsin, gemcitabine/doxorubicin, alemtuzumab |
| 3 | M | 66 | SS | ECP | NB-UVB, topical steroids |
| 4 | M | 85 | SS | ECP | Topical steroids |
| 5 | F | 71 | SS | Gemcitabine | ECP, bexarotene, topical steroids, IFNα-2b, vorinostat, romidepsin, belinostat |
| 6 | M | 73 | SS | Pralatrexate | Romidepsin, ECP, bexarotene, topical steroids |
| 7 | F | 61 | SS | ECP, bexarotene | Topical steroids, phototherapy |
| 8 | M | 77 | SS | Romidepsin, vorinostat | ECP, NB-UVB |
| 9 | M | 70 | SS | Pralatrexate | Romidepsin, vorinostat, mechlorethamine, ECP |
| 10 | M | 71 | MF | ECP, bexarotene | NB-UVB, topical steroids |
| 11 | F | 79 | SS | ECP, bexarotene, vorinostat, INFα-2b | Topical steroids |
| 12 | F | 64 | SS | ECP, bexarotene | Topical steroids |
| 13 | F | 76 | SS | ECP | None |
| 14 | M | 61 | MF | ECP, NB-UVB | None |
| 15 | M | 67 | SS | ECP, bexarotene | None |
| 16 | F | 40 | FMF | ECP, bexarotene | NB-UVB, TSEBT |
| 17 | M | 66 | SS | ECP, bexarotene, NB-UVB, topical steroids | None |
| 18 | F | 64 | MF | ECP, bexarotene, IFNα-2b, IFNγ-1b | None |
| 19 | M | 87 | MF | ECP | MTX, bexarotene, topical steroids |
| 20 | M | 85 | MF | ECP, bexarotene, NB-UVB | Topical steroids |
| 21 | M | 70 | MF (V) | EPOCH | None |
| 22 | M | 77 | MF | ECP, bexarotene | NB-UVB, topical steroids |
| 23 | M | 52 | MF | Gemcitabine | NB-UVB, bexarotene, vorinostat, ECP, IFNα-2b, romidepsin, |
| 24 | F | 62 | MF | ECP, bexarotene, NB-UVB, mechlorethamine | Topical steroids |
| 25 | M | 62 | MF | ECP, bexarotene | Topical steroids |
ECP, extracorporeal photopheresis; EPOCH, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; F, female; FMF, folliculotropic MF; IFN, interferon; M, male; MF, mycosis fungoides; MTX, methotrexate; NB-UVB, narrow band UV-B; PUVA, psoralen UV light A; SS, Sézary syndrome; TSEBT, total body electron beam therapy; V, visceral involvement.